Co-Authors
This is a "connection" page, showing publications co-authored by Mark Espeland and Lynne Wagenknecht.
Connection Strength
0.998
-
Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010 Sep 27; 170(17):1566-75.
Score: 0.186
-
Espeland MA, Carmichael O, Hayden K, Neiberg RH, Newman AB, Keller JN, Wadden TA, Rapp SR, Hill JO, Horton ES, Johnson KC, Wagenknecht L, Wing RR. Long-term Impact of Weight Loss Intervention on Changes in Cognitive Function: Exploratory Analyses from the Action for Health in Diabetes Randomized Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci. 2018 03 14; 73(4):484-491.
Score: 0.156
-
Belalcazar LM, Ballantyne CM, Lang W, Haffner SM, Rushing J, Schwenke DC, Pi-Sunyer FX, Tracy RP. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
Score: 0.097
-
Espeland MA, Regensteiner JG, Jaramillo SA, Gregg E, Knowler WC, Wagenknecht LE, Bahnson J, Haffner S, Hill J, Hiatt WR. Measurement characteristics of the ankle-brachial index: results from the Action for Health in Diabetes study. Vasc Med. 2008 Aug; 13(3):225-33.
Score: 0.080
-
Espeland MA, Evans GW, Wagenknecht LE, O'Leary DH, Zaccaro DJ, Crouse JR, Howard G, Haffner SM. Site-specific progression of carotid artery intimal-medial thickness. Atherosclerosis. 2003 Nov; 171(1):137-43.
Score: 0.058
-
Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol. 2003 Jun 01; 23(6):1035-41.
Score: 0.056
-
Bancks MP, Chen H, Balasubramanyam A, Bertoni AG, Espeland MA, Kahn SE, Pilla S, Vaughan E, Wagenknecht LE. Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Diabetes Care. 2021 May; 44(5):1203-1210.
Score: 0.048
-
Olson KL, Neiberg RH, Espeland MA, Johnson KC, Knowler WC, Pi-Sunyer X, Staiano AE, Wagenknecht LE, Wing RR. Waist Circumference Change During Intensive Lifestyle Intervention and Cardiovascular Morbidity and Mortality in the Look AHEAD Trial. Obesity (Silver Spring). 2020 10; 28(10):1902-1911.
Score: 0.046
-
Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, Byers T, Clark JM, Coday M, Egan C, Espeland MA, Foreyt JP, Garcia K, Goldman V, Gregg EW, Hazuda HP, Hesson L, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Knowler WC, Korytkowski M, Kure A, Lewis CE, Mantzoros C, Meacham M, Montez MG, Nathan DM, Pajewski N, Patricio J, Peters A, Xavier Pi-Sunyer F, Pownall H, Ryan DH, Safford M, Sedjo RL, Steinburg H, Vitolins M, Wadden TA, Wagenknecht LE, Wing RR, Wolff AC, Wyatt H, Yanovski SZ. Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity (Silver Spring). 2020 09; 28(9):1678-1686.
Score: 0.046
-
Jakicic JM, Horton ES, Curtis JM, Killean TM, Bray GA, Cheskin LJ, Johnson KC, Middelbeek RJW, Pi-Sunyer FX, Regensteiner JG, Ribisl PM, Wagenknecht L, Espeland MA. Abnormal Exercise Test or CVD History on Weight Loss or Fitness: the Look AHEAD Trial. Transl J Am Coll Sports Med. 2020; 5(12).
Score: 0.044
-
Gregg EW, Lin J, Bardenheier B, Chen H, Rejeski WJ, Zhuo X, Hergenroeder AL, Kritchevsky SB, Peters AL, Wagenknecht LE, Ip EH, Espeland MA. Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEAD Study. Diabetes Care. 2018 05; 41(5):1040-1048.
Score: 0.039
-
Wing RR, Espeland MA, Hazuda HP, Knowler WC, Wadden T. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care. 2016 Aug; 39(8):1345-55.
Score: 0.035
-
Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, Williamson D, Berkowitz RI, Kelley DE, Tomchee C, Hill JO, Kumanyika S. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006 May; 14(5):737-52.
Score: 0.034
-
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11; 369(2):145-54.
Score: 0.028
-
Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012 Jul; 20(7):1511-8.
Score: 0.025
-
Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007 Jun; 30(6):1374-83.
Score: 0.018